Content about Pharmaceutical industry

February 28, 2010
Merck's R&D pipeline gets a boost

Merck & Co.’s acquisition of Schering-Plough has delivered a big boost to the drug maker’s...

February 28, 2010
Reporters Notebook

GlaxoSmithKline has identified more than 5,500 rare diseases it potentially could target as part of...

February 28, 2010
The biggest Little Pharma in the world

With exception to those companies that are the first to win Food and Drug Administration...

February 25, 2010
Fougera receives FDA approval for generic Aldara

The Food and Drug Administration has given E. Fougera & Co. approval for the first...

February 25, 2010
Pfizer executive William Ringo to retire

A Pfizer executive credited with diversifying the company’s portfolio and helping create a joint venture...

February 24, 2010
Mylan reports surge in 2009 sales

Mylan had profits of $93.5 million in 2009, the generic drug maker announced Thursday in...

February 23, 2010
Report projects breast cancer drug sales to exceed $1 billion

An investigational drug for treating breast cancer will garner sales of more than $1 billion...

February 22, 2010
Endo reports 2009 profits

Endo Pharmaceuticals saw profits of $334.3 million in 2009, a 9% increase over 2008’s $305.7...

February 22, 2010
FDA declines to approve Bystolic as heart failure treatment

The Food and Drug Administration has declined to approve the use of a drug made...

February 22, 2010
FDA reviews Avandia safety data

The Food and Drug Administration is reviewing data from a large clinical study of a...

February 22, 2010
GPhA 'deeply disappointed' with 'pay-for-delay' ban in Obama healthcare bill

President Barack Obama’s proposed healthcare bill may have its supporters and detractors, but one group...

February 22, 2010
Watson reports 24% spike in profits

Watson Pharmaceuticals had profits of $348.8 million for 2009, according to annual financial results announced...

February 21, 2010
Report: FDA to speed up generic drug approval process

The Food and Drug Administration hopes to accelerate the review process for generic drugs, according...

February 21, 2010
Senate report: GSK diabetes drug poses heart attack risk; draws response from drug maker

A report released over the weekend by a Senate committee linked a drug used to...

February 20, 2010
Watson seeks FDA approval for depression generic

Watson Pharmaceuticals has filed a regulatory approval application with the Food and Drug Administration for...

February 18, 2010
GSK responds to FDA's labeling recommendations for asthma drugs

British drug maker GlaxoSmithKline issued a response to new labeling requirements proposed by the Food...

February 17, 2010
Novartis to change name, repackage Maalox Total Relief

Choosing the wrong liquid Maalox product can have harmful consequences, the Food and Drug Administration...

February 16, 2010
Drug makers sign agreement to develop rheumatoid arthritis drug

Anglo-Swedish drug maker AstraZeneca and American drug maker Rigel Pharmaceuticals have signed a global licensing...

February 16, 2010
Merck appoints EVP and president of consumer health care

Merck & Co. has appointed former Johnson & Johnson executive Bridgette Heller to serve as...

February 16, 2010
Teva full-year profits up 22%

Teva Pharmaceutical Industries got a big boost in profits in 2009 compared with 2008, the...

February 15, 2010
FTC pushes to end patent settlements, vexing branded, generic drug industry

On a lot of issues, the branded and generic drug industries agree about as readily...

February 11, 2010
Drug makers seek high-tech consumer connections

Advertisements on television for drugs have become ubiquitous, but some drug makers are looking for...

February 11, 2010
Investors should remember the patent cliff

Some investors quoted in published reports foresee huge gains for such retail pharmacy chains as...

WHAT IT MEANS AND WHY ITS IMPORTANT Some investors quoted in published reports foresee huge gains for such retail pharmacy chains as CVS and Walgreens, as blockbuster drugs like Pfizer’s Lipitor (atorvastatin) and Sanofi-Aventis’ and Bristol-Myers Squibb’s Plavix (clopidogrel bisulfate) come off patent and face generic competition, but they would do well to remember an important factor: the patent cliff.

February 10, 2010
PricewaterhouseCoopers projects expansion of retail clinics, offerings

Traditional care delivery models will continue to give way to alternative care delivery models, such...

February 10, 2010
Sanofi-Aventis may pursue generic, OTC businesses

Pfizer, Merck & Co. and Roche have made big mega-acquisitions. Eli Lilly has pumped money...